These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23797977)

  • 1. Whither hope for pharmacological treatment of Charcot-Marie-Tooth disease type 1A?
    Patel PI; Pleasure D
    JAMA Neurol; 2013 Aug; 70(8):969-71. PubMed ID: 23797977
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
    Lewis RA; McDermott MP; Herrmann DN; Hoke A; Clawson LL; Siskind C; Feely SM; Miller LJ; Barohn RJ; Smith P; Luebbe E; Wu X; Shy ME;
    JAMA Neurol; 2013 Aug; 70(8):981-7. PubMed ID: 23797954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?
    Pareyson D; Solari A
    Lancet Neurol; 2009 Dec; 8(12):1075-7. PubMed ID: 19818689
    [No Abstract]   [Full Text] [Related]  

  • 4. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
    Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM
    Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
    Passage E; Norreel JC; Noack-Fraissignes P; Sanguedolce V; Pizant J; Thirion X; Robaglia-Schlupp A; Pellissier JF; Fontés M
    Nat Med; 2004 Apr; 10(4):396-401. PubMed ID: 15034573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
    Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O
    Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ascorbic acid: a first generation drug for Charcot-Marie-Tooth disease].
    Fontès M
    Med Sci (Paris); 2004 Oct; 20(10):843-4. PubMed ID: 15461953
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ascorbic Acid and Charcot-Marie-Tooth Disease].
    Noto Y
    Brain Nerve; 2015 Oct; 67(10):1241-6. PubMed ID: 26450076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands.
    Reilly MM; de Jonghe P; Pareyson D
    Neuromuscul Disord; 2006 Jun; 16(6):396-402. PubMed ID: 16684603
    [No Abstract]   [Full Text] [Related]  

  • 10. Ascorbic acid for treatment of CMT1A: the jury is still out.
    Shy M
    Lancet Neurol; 2009 Jun; 8(6):505-7. PubMed ID: 19427270
    [No Abstract]   [Full Text] [Related]  

  • 11. Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acid.
    Burns J; Ouvrier RA; Yiu EM; Ryan MM
    J Peripher Nerv Syst; 2011 Sep; 16(3):272-4. PubMed ID: 22003943
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of life in children with CMT type 1A.
    Ramchandren S; Shy ME; Finkel RS
    Lancet Neurol; 2009 Oct; 8(10):880-1; author reply 881. PubMed ID: 19747650
    [No Abstract]   [Full Text] [Related]  

  • 13. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.
    Toth C
    Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascorbic acid for treatment in CMT1A: what's next?
    de Visser M; Verhamme C
    Lancet Neurol; 2011 Apr; 10(4):291-3. PubMed ID: 21393064
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatments for denervating diseases.
    Pleasure D
    J Child Neurol; 2005 Mar; 20(3):258-62. PubMed ID: 15832625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
    Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
    Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patients.
    Menotti F; Laudani L; Damiani A; Mignogna T; Macaluso A
    Prosthet Orthot Int; 2014 Oct; 38(5):387-92. PubMed ID: 24100074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurophysiology and molecular genetics of Charcot-Marie-Tooth type 1 neuropathy in Croatian children: follow-up study.
    Barisić N; Mihatov I
    Croat Med J; 2000 Sep; 41(3):306-13. PubMed ID: 10962051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.
    Rose KJ; Burns J; North KN
    J Child Neurol; 2010 Apr; 25(4):463-8. PubMed ID: 19671887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonography of the median nerve in Charcot-Marie-Tooth disease.
    Martinoli C; Schenone A; Bianchi S; Mandich P; Caponetto C; Abbruzzese M; Derchi LE
    AJR Am J Roentgenol; 2002 Jun; 178(6):1553-6. PubMed ID: 12034637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.